Aneurysmal Subarachnoid Hemorrhage Drugs Market By Drug Class: Global Opportunity Analysis and Industry Forecast, 2020-2030

Report
180 Pages
March 2022
Region: Global
Allied Market Research
ID: 5640369

The global aneurysmal subarachnoid hemorrhage drugs market was valued at $323.51 million in 2020, and is projected to reach $456.31 million by 2030, registering a CAGR of 3.6% from 2021 to 2030.

Aneurysmal subarachnoid hemorrhage (aSAH) is a condition in which brain aneurysm ruptures, resulting in bleeding in the subarachnoid space. In severe cases, bleeding may cause brain damage, which leads to paralysis, coma, or even death. The National Institutes of Health (NIH) stated that aSAH is a global health concern, with high fatality and permanent disability rates.

The main symptoms of aSAH include severe headache, nausea, vomiting, stiff neck, photophobia, blurred vision, loss of consciousness, and seizures. The diagnosis process of aSAH includes computed tomography (CT), lumbar puncture, angiogram, and magnetic resonance imaging (MRI).

The major factors that drives the global aSAH market are rise in prevalence of diseases such as stroke & hypertension, and surge in geriatric population. In addition, lifestyle that include increase in alcohol consumption and smoking increase risk of aSAH, which, in turn, stimulates the market growth. However, associated side effects of drugs and medication consumed during the treatment of aSAH restrain the market growth. Furthermore, increase in awareness regarding the treatment of aSAH is expected to provide numerous opportunities for the market growth in future.

The aSAH market is segmented on the basis of drug class and region. On the basis of drug class, the market is segmented into opioid analgesics, calcium channel blockers, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market.

Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity increase demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the product demand.

The major players operating in the global aSAH drugs market are Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc. These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current aSAH drugs market trends, estimations, and dynamics of the aneurysmal subarachnoid hemorrhage drugs market analysis from 2020 to 2030 to identify the prevailing aneurysmal subarachnoid hemorrhage drugs market opportunities.
The aSAH Drugs Market analysis research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the aneurysmal subarachnoid hemorrhage drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global aSAH drugs industry trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Calcium Channel Blocker
Anticonvulsant
Stool Softener
Osmotic Agents/Diuretics
Other Drugs
Opioid Analgesic

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
South Africa
Rest of LAMEA

Key Market Players

Azurity Pharmaceuticals
Johnson and Johnson
medicure
NeurOp
orexo ab
Pfizer, Inc.
Pharmaxis, Ltd.
Sun Pharmaceutical Industries Ltd.
teva pharmaceutical industries ltd.
Vitrais, Inc

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS

4.1 Overview
4.1.1 Market size and forecast
4.2 Opioid Analgesic
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Calcium Channel Blocker
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Anticonvulsant
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Stool Softener
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Osmotic Agents/Diuretics
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Other Drugs
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country

CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION

5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key trends and opportunities
5.2.2 North America Market size and forecast, by Drug Class
5.2.3 North America Market size and forecast, by country
5.2.3.1 U.S.
5.2.3.1.1 Market size and forecast, by Drug Class
5.2.3.2 Canada
5.2.3.2.1 Market size and forecast, by Drug Class
5.2.3.3 Mexico
5.2.3.3.1 Market size and forecast, by Drug Class
5.3 Europe
5.3.1 Key trends and opportunities
5.3.2 Europe Market size and forecast, by Drug Class
5.3.3 Europe Market size and forecast, by country
5.3.3.1 Germany
5.3.3.1.1 Market size and forecast, by Drug Class
5.3.3.2 France
5.3.3.2.1 Market size and forecast, by Drug Class
5.3.3.3 United Kingdom
5.3.3.3.1 Market size and forecast, by Drug Class
5.3.3.4 Italy
5.3.3.4.1 Market size and forecast, by Drug Class
5.3.3.5 Rest of Europe
5.3.3.5.1 Market size and forecast, by Drug Class
5.4 Asia-Pacific
5.4.1 Key trends and opportunities
5.4.2 Asia-Pacific Market size and forecast, by Drug Class
5.4.3 Asia-Pacific Market size and forecast, by country
5.4.3.1 Japan
5.4.3.1.1 Market size and forecast, by Drug Class
5.4.3.2 China
5.4.3.2.1 Market size and forecast, by Drug Class
5.4.3.3 Australia
5.4.3.3.1 Market size and forecast, by Drug Class
5.4.3.4 India
5.4.3.4.1 Market size and forecast, by Drug Class
5.4.3.5 Rest of Asia-Pacific
5.4.3.5.1 Market size and forecast, by Drug Class
5.5 LAMEA
5.5.1 Key trends and opportunities
5.5.2 LAMEA Market size and forecast, by Drug Class
5.5.3 LAMEA Market size and forecast, by country
5.5.3.1 Brazil
5.5.3.1.1 Market size and forecast, by Drug Class
5.5.3.2 Turkey
5.5.3.2.1 Market size and forecast, by Drug Class
5.5.3.3 South Africa
5.5.3.3.1 Market size and forecast, by Drug Class
5.5.3.4 Rest of LAMEA
5.5.3.4.1 Market size and forecast, by Drug Class

CHAPTER 6: COMPANY LANDSCAPE

6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments

CHAPTER 7: COMPANY PROFILES

7.1 Azurity Pharmaceuticals
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 Johnson and Johnson
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 medicure
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 NeurOp
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 orexo ab
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 Pfizer, Inc.
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 Pharmaxis, Ltd.
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 Sun Pharmaceutical Industries Ltd.
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 teva pharmaceutical industries ltd.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 Vitrais, Inc
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments

LIST OF TABLES

Table 1. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Drug Class, 2020-2030, ($Million)
Table 2. Aneurysmal Subarachnoid Hemorrhage Drugs Market Revenue, for Opioid Analgesic, by Region, 2020-2030, ($Million)
Table 3. Aneurysmal Subarachnoid Hemorrhage Drugs Market Opioid Analgesic by Country, 2020-2030, ($Million)
Table 4. Aneurysmal Subarachnoid Hemorrhage Drugs Market Revenue, for Calcium Channel Blocker, by Region, 2020-2030, ($Million)
Table 5. Aneurysmal Subarachnoid Hemorrhage Drugs Market Calcium Channel Blocker by Country, 2020-2030, ($Million)
Table 6. Aneurysmal Subarachnoid Hemorrhage Drugs Market Revenue, for Anticonvulsant, by Region, 2020-2030, ($Million)
Table 7. Aneurysmal Subarachnoid Hemorrhage Drugs Market Anticonvulsant by Country, 2020-2030, ($Million)
Table 8. Aneurysmal Subarachnoid Hemorrhage Drugs Market Revenue, for Stool Softener, by Region, 2020-2030, ($Million)
Table 9. Aneurysmal Subarachnoid Hemorrhage Drugs Market Stool Softener by Country, 2020-2030, ($Million)
Table 10. Aneurysmal Subarachnoid Hemorrhage Drugs Market Revenue, for Osmotic Agents/Diuretics, by Region, 2020-2030, ($Million)
Table 11. Aneurysmal Subarachnoid Hemorrhage Drugs Market Osmotic Agents/Diuretics by Country, 2020-2030, ($Million)
Table 12. Aneurysmal Subarachnoid Hemorrhage Drugs Market Revenue, for Other Drugs, by Region, 2020-2030, ($Million)
Table 13. Aneurysmal Subarachnoid Hemorrhage Drugs Market Other Drugs by Country, 2020-2030, ($Million)
Table 14. Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Region, 2020-2030, ($Million)
Table 15. North America Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Drug Class, 2020-2030, ($Million)
Table 16. North America Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Country, 2020-2030, ($Million)
Table 17. U.S. Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 18. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 19. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 20. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Drug Class, 2020-2030, ($Million)
Table 21. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Country, 2020-2030, ($Million)
Table 22. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 23. France Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 24. United Kingdom Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 25. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 26. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 27. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Drug Class, 2020-2030, ($Million)
Table 28. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Country, 2020-2030, ($Million)
Table 29. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 30. China Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 31. Australia Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 32. India Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 33. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 34. LAMEA Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Drug Class, 2020-2030, ($Million)
Table 35. LAMEA Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Country, 2020-2030, ($Million)
Table 36. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 37. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 38. South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 39. Rest of LAMEA Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class 2020-2030, ($Million)
Table 40. Azurity Pharmaceuticals: Company Snapshot
Table 41. Azurity Pharmaceuticals: Operating Segments
Table 42. Azurity Pharmaceuticals: Product Portfolio
Table 43. Azurity Pharmaceuticals: Net Sales
Table 44. Azurity Pharmaceuticals: Key Stratergies
Table 45. Johnson and Johnson: Company Snapshot
Table 46. Johnson and Johnson: Operating Segments
Table 47. Johnson and Johnson: Product Portfolio
Table 48. Johnson and Johnson: Net Sales
Table 49. Johnson and Johnson: Key Stratergies
Table 50. Medicure: Company Snapshot
Table 51. Medicure: Operating Segments
Table 52. Medicure: Product Portfolio
Table 53. Medicure: Net Sales
Table 54. Medicure: Key Stratergies
Table 55. Neurop: Company Snapshot
Table 56. Neurop: Operating Segments
Table 57. Neurop: Product Portfolio
Table 58. Neurop: Net Sales
Table 59. Neurop: Key Stratergies
Table 60. Orexo Ab: Company Snapshot
Table 61. Orexo Ab: Operating Segments
Table 62. Orexo Ab: Product Portfolio
Table 63. Orexo Ab: Net Sales
Table 64. Orexo Ab: Key Stratergies
Table 65. Pfizer, Inc.: Company Snapshot
Table 66. Pfizer, Inc.: Operating Segments
Table 67. Pfizer, Inc.: Product Portfolio
Table 68. Pfizer, Inc.: Net Sales
Table 69. Pfizer, Inc.: Key Stratergies
Table 70. Pharmaxis, Ltd.: Company Snapshot
Table 71. Pharmaxis, Ltd.: Operating Segments
Table 72. Pharmaxis, Ltd.: Product Portfolio
Table 73. Pharmaxis, Ltd.: Net Sales
Table 74. Pharmaxis, Ltd.: Key Stratergies
Table 75. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 76. Sun Pharmaceutical Industries Ltd.: Operating Segments
Table 77. Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 78. Sun Pharmaceutical Industries Ltd.: Net Sales
Table 79. Sun Pharmaceutical Industries Ltd.: Key Stratergies
Table 80. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 81. Teva Pharmaceutical Industries Ltd.: Operating Segments
Table 82. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 83. Teva Pharmaceutical Industries Ltd.: Net Sales
Table 84. Teva Pharmaceutical Industries Ltd.: Key Stratergies
Table 85. Vitrais, Inc: Company Snapshot
Table 86. Vitrais, Inc: Operating Segments
Table 87. Vitrais, Inc: Product Portfolio
Table 88. Vitrais, Inc: Net Sales
Table 89. Vitrais, Inc: Key Stratergies

LIST OF FIGURES

Figure 1. Aneurysmal Subarachnoid Hemorrhage Drugs Market Segmentation
Figure 2. Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030
Figure 3. Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Aneurysmal Subarachnoid Hemorrhage Drugs Market:Drivers, Restraints and Opportunities
Figure 11. Aneurysmal Subarachnoid Hemorrhage Drugs Market, by Drug Class, 2020 (%)
Figure 12. Comparative Share Analysis of Opioid Analgesic Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 (%)
Figure 13. Comparative Share Analysis of Calcium Channel Blocker Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 (%)
Figure 14. Comparative Share Analysis of Anticonvulsant Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 (%)
Figure 15. Comparative Share Analysis of Stool Softener Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 (%)
Figure 16. Comparative Share Analysis of Osmotic Agents/Diuretics Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 (%)
Figure 17. Comparative Share Analysis of Other Drugs Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 (%)
Figure 18. Aneurysmal Subarachnoid Hemorrhage Drugs Market by Region, 2020
Figure 19. U.S. Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 20. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 21. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 22. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 23. France Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 24. United Kingdom Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 25. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 26. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 27. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 28. China Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 29. Australia Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 30. India Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 31. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 32. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 33. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 34. South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 35. Rest of LAMEA Aneurysmal Subarachnoid Hemorrhage Drugs Market, 2020-2030 ($Million)
Figure 36. Top Winning Strategies, by Year
Figure 37. Top Winning Strategies, by Development
Figure 38. Top Winning Strategies, by Company
Figure 39. Product Mapping of Top 10 Players
Figure 40. Competitive Dashboard
Figure 41. Competitive Heatmap of Top 10 Key Players
Figure 42. Azurity Pharmaceuticals.: Net Sales, ($Million)
Figure 43. Johnson and Johnson.: Net Sales, ($Million)
Figure 44. Medicure.: Net Sales, ($Million)
Figure 45. Neurop.: Net Sales, ($Million)
Figure 46. Orexo Ab.: Net Sales, ($Million)
Figure 47. Pfizer, Inc. Net Sales, ($Million)
Figure 48. Pharmaxis, Ltd. Net Sales, ($Million)
Figure 49. Sun Pharmaceutical Industries Ltd. Net Sales, ($Million)
Figure 50. Teva Pharmaceutical Industries Ltd. Net Sales, ($Million)
Figure 51. Vitrais, Inc.: Net Sales, ($Million)

Executive Summary

According to this report titled, 'Aneurysmal Subarachnoid Hemorrhage Drugs Market,' the aneurysmal subarachnoid hemorrhage drugs market size was valued at $323.51 million in 2020, and is estimated to reach $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030.
Aneurysmal subarachnoid hemorrhage (aSAH) is a type of stroke, which is caused by bleeding in subarachnoid space of the brain. Major reasons for aneurysmal subarachnoid hemorrhage include brain aneurysm, arteriovenous malformation, or head injury.

Rise in the cases of berry aneurysm, high blood pressure, drug use, and rise in geriatric population are the major factors that contribute to the growth of the market. Moreover, increase in prevalence of hypertension and stroke boost the market growth. ASAH is prevalent among higher age group mostly in women. The population is predicted to encounter numerous severe disorders with increase in age, which include stroke and cerebral aneurysms. Hence, surge in geriatric population is expected to fuel the growth of aSAH Drugs Market size across globe throughout the forecast period.

Medication or drugs used during treatment of aSAH prevent blockages in the brain; however, they have certain side effects. For instance, nimodipine is a key drug that reduces chances of secondary cerebral ischemia, which is one of the major complications of subarachnoid hemorrhage. However, this drug has certain side effects, which include flushing, feeling sick, increasing heart rate, headaches, and rash. This factor is expected to impede growth of the aSAH market.

Subarachnoid hemorrhage (SAH) is a type of stroke, which is caused by a ruptured aneurysm, arteriovenous malformation (AVM), or head injury. One-third of the total patients survive with good recovery, another one-third survive with a disability, and remaining one-third die before receiving medical attention of total patient base of subarachnoid hemorrhage. Despite widespread availability of modern diagnostic and treatment modalities, many patients fail to reach specialized centers until hours or days following hemorrhage. Thus, there is a need to create general awareness among primary and community physicians about optimal diagnostic and therapeutic maneuvers in patients with suspected SAH. Campaigns that include brain aneurysmal awareness month are expected to create lucrative opportunities for the growth of the aSAH drugs market.

The aSAH drugs market share in this report is studied on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. The calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market.

Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act along with well-planned reimbursement policies contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increase in demand for these devices. However, Asia-Pacific aSAH Drugs Industry is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China with higher disposable incomes fuel the demand for the products.

Companies Mentioned

Azurity Pharmaceuticals
Johnson and Johnson
medicure
NeurOp
orexo ab
Pfizer, Inc.
Pharmaxis, Ltd.
Sun Pharmaceutical Industries Ltd.
teva pharmaceutical industries ltd.
Vitrais, Inc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic news articles and other related releases for market evaluation
Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

LOADING...

Table Information

Report Attribute	Details
No. of Pages	180
Published	March 2022
Forecast Period	2020 - 2030
Estimated Market Value ( USD ) in 2020	$ 323.51 million
Forecasted Market Value ( USD ) by 2030	$ 456.31 million
Compound Annual Growth Rate	3.5%
Regions Covered	Global
No. of Companies Mentioned	10

PURCHASE OPTIONS

Single User License PDF

1 - 5 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5578EUR$5,769USD£4,759GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6236EUR$6,450USD£5,321GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€10631EUR$10,995USD£9,071GBP

Key Benefits For Stakeholders

Key Market Segments

By Drug Class

By Region

Key Market Players

Table of Contents

Executive Summary

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Subarachnoid Hemorrhage - Pipeline Insight, 2024

Aneurysmal Subarachnoid Hemorrhage - Pipeline Insight, 2024

Global Intracranial Aneurysm Market Analysis & Forecast to 2024-2034

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-morbidity Factors Part A. International Review of Neurobiology Volume 171

Global Neurodegenerative Drugs Market by Drug Class (Cholinesterase Inhibitors, Decarboxylase Inhibitors, Dopamine Agonist), Indication (Alzheimer's Disease, Dementia, Huntington's Disease), Sales Channel - Forecast 2024-2030